A newly unveiled map reveals the devastating impact on the UK if nuclear bombs were to hit specific locations. Last weekend, ...

Vaxxas, a clinical-stage biotechnology company, has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim ...